Europe NGS Automation Market by Product (Platform, Consumables), Sequencing Type (Whole Genome, Exome, Targeted), Application (Drug Discovery, Diagnostics), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic) - Forecast to 2030

The Europe NGS Automation Market is projected to reach $380.4 million by 2030, at a CAGR of 13.4% from 2024 to 2030. Next-generation sequencing (NGS) includes sample pre-processing, library preparation, sequencing, and bioinformatics. The library preparation step is critical in NGS workflow; however, it is still time-consuming and repetitive despite ongoing technical advancements in high-throughput sequencing. The library preparation step has numerous repetitive steps that require small volumes to be pipetted with high precision. This process makes it highly prone to manual errors, compromising the entire NGS process. Automation of library preparation can increase efficiency, generate more consistent results, and increase lab efficiency. NGS automation also helps maintain turnaround times and increase sample throughput.

The main factors driving the NGS automation market are the increasing demand for automation in NGS workflow, the rising incidences of cancer, and the increasing R&D investments and healthcare expenditure. Furthermore, the increasing applications of next-generation sequencing and the rising number of collaborations between companies to develop library preparation protocols are expected to provide significant growth opportunities for this market.

However, the high cost of automation workstations is expected to restrain the growth of this market to a notable extent. In addition, factors such as regulatory & standardization concerns in diagnostic testing and the requirement of high-skilled personnel for operating automation software are the major challenges to the growth of this market.

Click here to: Get Free Sample Pages of this Report

Growing Demand for Optimized & Streamlined NGS Workflows to Drive Adoption

The emergence of next-generation sequencing (NGS) technology has led to a significant decrease in DNA sequencing costs, making the technology accessible to scientists worldwide. However, despite the significant decrease in costs, there are still some challenges in the manual processes used in sequencing technology. The library preparation step is highly time-consuming and prone to human error, making the process inefficient for genomics laboratories in terms of time and cost. Automating such processes can increase efficiency and reduce sequencing costs.

Automating NGS library preparation helps researchers improve their library quality and achieve consistent yields, enabling reliable and reproducible NGS data generation. NGS automation also enhances efficiency in terms of time and cost. The risk of contamination is greatly reduced by reducing human interactions with the reagents and samples. The rising need for accuracy, scalability, and compliance with regulatory standards is expected to drive the demand for NGS automation in Europe.

Rising Prevalence of Cancer to Drive Market Growth

Cancer is a prominent cause of death and a major obstacle to improving life expectancy in every country worldwide. The International Agency for Research on Cancer (IARC) estimates that globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women succumb to the disease. Europe also faces a similar scenario of rising cancer prevalence. According to IARC, the number of new cancer cases in Europe is estimated to increase from 4.39 million in 2020 to 4.91 million by 2030.

NGS allows comprehensive profiling of a patient's tumor DNA, which guides the development of personalized treatment plans. As the number of cancer cases continues to rise, there is a growing need for NGS automation solutions to efficiently process and analyze the vast amount of genetic data generated in cancer diagnostics and research. Additionally, the rising cancer prevalence creates a high demand for new cancer drugs. Therefore, pharmaceutical and biotechnology companies require efficient and high-throughput NGS automation solutions for research and development.

Thus, the rising prevalence of cancer and increasing efforts to develop targeted treatment approaches are expected to drive the NGS automation market in Europe.

Key Findings in the Europe NGS Automation Market Study:

The Workstation/Robotic Platform Segment to Dominate the Market in 2024

Based on product, the Europe NGS automation market is segmented into workstations/robotic platforms and reagents & consumables. In 2024, the workstations/robotic platforms segment is expected to account for the larger share of the NGS automation market in Europe. The large market share of this segment is attributed to factors such as the increasing pharmaceutical R&D expenditure and the rising demand for automation of NGS library preparation due to its benefits, such as increased efficiency and the ability to generate consistent and reproducible results.

The Drug Discovery Segment to Dominate the Europe NGS Automation Market in 2024

Based on application, the Europe NGS automation market is segmented into drug discovery, clinical diagnostics (oncology, infectious diseases, reproductive health, and other clinical diagnostics), and other applications.  In 2024, the drug discovery segment is expected to account for the largest share of the NGS automation market in Europe. The large market share of this segment is attributed to the increased use of NGS technologies in drug discovery and the potential of NGS to cut down drug development costs and reduce the duration of drug discoveries. Next-generation sequencing has ushered in a new era of gene-based drug development by enabling high-throughput analysis of genotype-phenotype relationships in human populations, boosting the demand for NGS automation.

The Whole Genome Sequencing Segment to Dominate the Europe NGS Automation Market in 2024

Based on sequencing type, the NGS Automation market is segmented into whole genome sequencing, whole exome sequencing, targeted genome sequencing, and other sequencing types. In 2024, the whole genome sequencing segment is expected to account for the largest share of the NGS automation market in Europe. The large market share of this segment is attributed to the rising need to lower the per-sample cost of whole-genome sequencing by automating the NGS library preparation. Library preparation activities such as DNA extraction, quantification, fragmentation, normalization, purification, and quality control are labor-intensive and slow down the generation of sequencing data; hence, there is a rising demand for the adoption of NGS automation solutions.

The Pharmaceutical and Biotechnology Companies Segment to Dominate the Europe NGS Automation Market in 2024

Europe NGS Automation market is segmented into hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the NGS automation market in Europe. The large share of this segment is attributed to the increasing pharmaceutical and biotechnology R&D expenditure, growing adoption of NGS in drug discovery and development, and increased government funding for research activities. Furthermore, the increasing investments by pharmaceutical and biotechnology companies in advanced NGS automation systems are one of the major factors driving the growth of this segment.

Key Players

The report includes a competitive landscape based on an in-depth assessment of offerings and growth strategies adopted by key market players in the last 3–4 years.The key players operating in the Europe NGS Automation market are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), PRIMADAG SAS (France), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific Inc. (U.S.), and F. Hoffmann-La Roche AG (Switzerland).

Scope of the Report:

Europe NGS Automation Market, by Product

• Workstation/Robotic Platform
• Reagents & Consumables

Europe NGS Automation Market, by Application

• Drug Discovery
• Clinical Diagnostics
  • Oncology
  • Infectious Diseases
  • Reproductive Health
  • Other Clinical Diagnostics
• Other Applications

Europe NGS Automation Market, by Sequencing Type

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Genome Sequencing
• Other Sequencing Types

Europe NGS Automation Market, by End User

• Hospitals & Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies
• Academic Research Institutes
• Others End Users

Europe NGS Automation Market, by Country

• Germany
• France
• U.K.
• Italy
• Spain
• Switzerland
• Netherlands
• Belgium
• Rest of Europe (RoE)

Key questions answered in the report: